Given the current inadequate performance demonstrated by a single modality in assessing the methylation status of the MGMT promoter, this study reflects deeply and recognizes that relying on the imaging data of one particular modality alone does have significant shortcomings in comprehensively capturing and resolving the complex brain tumor features (29, 30). The gene discussed is MGMT; the disease is brain neoplasm.